Skip to main content
Clinical Trials/JPRN-UMIN000048054
JPRN-UMIN000048054
Recruiting
未知

In real-world clinical practice current status of refractory with topical antifungal drug therapy on onychomycosis and efficacy and safety of fosravuconazole switching treatment: a retrospective study - In real-world clinical practice current status of refractory with topical antifungal drug therapy on onychomycosis and efficacy and safety of fosravuconazole switching treatment: a retrospective study

Sato Pharmaceutical Co., Ltd0 sites88 target enrollmentJune 14, 2022
ConditionsOnychomycosis

Overview

Phase
未知
Intervention
Not specified
Conditions
Onychomycosis
Sponsor
Sato Pharmaceutical Co., Ltd
Enrollment
88
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 14, 2022
End Date
May 31, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Sato Pharmaceutical Co., Ltd

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Patients with significant thickening, deformation, or discoloration of the nails due to diseases such as palmoplantar pustulosis psoriasis vulgaris, lichen planus, pachyonychia , subungual tumor, or onychogryphosis 2\) Patients who refuse to provide medical information for this study

Outcomes

Primary Outcomes

Not specified

Similar Trials